RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- Acronyms RainbowExt
- Sponsors Novartis
- 12 Oct 2017 Planned End Date changed from 1 Sep 2022 to 30 Oct 2022.
- 12 Oct 2017 Planned primary completion date changed from 1 Sep 2022 to 30 Oct 2022.
- 01 Apr 2017 The trial has been completed in Greece.